Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Ryan, John T; Nakayama, Masao; Gleeson, Ian; Mannion, Liam; Geso, Moshi; Kelly, Jennifer; Ng, Sweet Ping; Hardcastle, Nicholas

doi:10.1186/s13014-022-02146-8

Table 1 Study characteristics

From: Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Study name	Location	Citations	Data		Par n	Study type					Q	Aim
			Conf. abstract	Journal	Participants	RCT Phase 1	RCT Phase 2	RCT Phase 3	Prosp. cohort	Retro. cohort	Study Quality	Standard target delineation	Dose escalation	Organs at risk sparing	Recurrences &treated volumes	Functional volumes& planning volumes	Functional volumes& survival	Radiomic features
Niyazi	Europe	[32]	\(\checkmark\)		17					\(\checkmark\)						\(\checkmark\)
Niyazi	Europe	[33]		\(\checkmark\)	17					\(\checkmark\)	9				\(\checkmark\)	\(\checkmark\)
Piroth	Europe	[34]		\(\checkmark\)	44				\(\checkmark\)		9		\(\checkmark\)				\(\checkmark\)
		[35]	\(\checkmark\)		22	\(\checkmark\)	\(\checkmark\)						\(\checkmark\)				\(\checkmark\)
		[36]		\(\checkmark\)	22		\(\checkmark\)						\(\checkmark\)				\(\checkmark\)
		[37]		\(\checkmark\)	13		\(\checkmark\)								\(\checkmark\)
Laouiti	Europe	[38]	\(\checkmark\)		12	\(\checkmark\)	\(\checkmark\)				N	\(\checkmark\)	\(\checkmark\)
Miwa	Asia	[39]	\(\checkmark\)		51	\(\checkmark\)	\(\checkmark\)				N	\(\checkmark\)	\(\checkmark\)
Munck Af	Europe	[40]		\(\checkmark\)	54				\(\checkmark\)			\(\checkmark\)				\(\checkmark\)
Rosenschold	Europe	[41]		\(\checkmark\)	190					\(\checkmark\)	9	\(\checkmark\)				\(\checkmark\)	\(\checkmark\)
Lundemann	Europe	[42]	\(\checkmark\)		66					\(\checkmark\)		\(\checkmark\)			\(\checkmark\)	\(\checkmark\)
		[43]		\(\checkmark\)	66					\(\checkmark\)		\(\checkmark\)			\(\checkmark\)	\(\checkmark\)
		[44]		\(\checkmark\)	14				\(\checkmark\)		9				\(\checkmark\)			\(\checkmark\)
Poulsen	Europe	[45]	\(\checkmark\)		146					\(\checkmark\)		\(\checkmark\)					\(\checkmark\)
Poulsen	Europe	[46]		\(\checkmark\)	146					\(\checkmark\)	7	\(\checkmark\)					\(\checkmark\)
Harat	Europe	[47]		\(\checkmark\)	29					\(\checkmark\)	9				\(\checkmark\)	\(\checkmark\)
Hayes	Aus/NZ	[48]		\(\checkmark\)	24					\(\checkmark\)	8	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)
Fleischmann	Europe	[49]		\(\checkmark\)	36					\(\checkmark\)	9				\(\checkmark\)	\(\checkmark\)
Matsuo	Asia	[50]		\(\checkmark\)	32				\(\checkmark\)		9					\(\checkmark\)
Matsuo	Asia	[51]	\(\checkmark\)		32				\(\checkmark\)							\(\checkmark\)
Vigil	Europe	[52]	\(\checkmark\)		40					\(\checkmark\)			\(\checkmark\)		\(\checkmark\)	\(\checkmark\)	\(\checkmark\)
Vigil	Europe	[53]	\(\checkmark\)		50					\(\checkmark\)	9		\(\checkmark\)		\(\checkmark\)	\(\checkmark\)	\(\checkmark\)
Hirata	Asia	[54]	\(\checkmark\)		25					\(\checkmark\)					\(\checkmark\)	\(\checkmark\)	\(\checkmark\)
Hirata	Asia	[55]		\(\checkmark\)	25					\(\checkmark\)	9				\(\checkmark\)	\(\checkmark\)	\(\checkmark\)
Christensen	USA	[56]	\(\checkmark\)		6					\(\checkmark\)					\(\checkmark\)	\(\checkmark\)
Christensen	USA	[57]		\(\checkmark\)	11					\(\checkmark\)	7				\(\checkmark\)	\(\checkmark\)
Kosztyla	Canada	[58]		\(\checkmark\)	19				\(\checkmark\)		6				\(\checkmark\)	\(\checkmark\)
Brinkmann	USA	[59]	\(\checkmark\)		32		\(\checkmark\)									\(\checkmark\)
		[60]	\(\checkmark\)		77		\(\checkmark\)					\(\checkmark\)	\(\checkmark\)
		[61]	\(\checkmark\)		75		\(\checkmark\)				N	\(\checkmark\)	\(\checkmark\)				\(\checkmark\)
Windisch	Europe	[62]	\(\checkmark\)		13				\(\checkmark\)							\(\checkmark\)
Windisch	Europe	[63]		\(\checkmark\)	13				\(\checkmark\)		7					\(\checkmark\)
Munshi	Asia	[64]		\(\checkmark\)	24					\(\checkmark\)	7					\(\checkmark\)
Wahl	USA	[65]		\(\checkmark\)	52					\(\checkmark\)	9				\(\checkmark\)	\(\checkmark\)	\(\checkmark\)
Kim	USA	[66]	\(\checkmark\)		20		\(\checkmark\)						\(\checkmark\)				\(\checkmark\)
		[67]		\(\checkmark\)	12		\(\checkmark\)						\(\checkmark\)				\(\checkmark\)
		[68]	\(\checkmark\)		26		\(\checkmark\)				9		\(\checkmark\)				\(\checkmark\)
Berberat	Europe	[69]		\(\checkmark\)	13					\(\checkmark\)	8				\(\checkmark\)	\(\checkmark\)
Wang	Asia	[70]		\(\checkmark\)	20					\(\checkmark\)	8			\(\checkmark\)
Zhang	USA	[71]	\(\checkmark\)		100				\(\checkmark\)		N	\(\checkmark\)
Altabella	Europe	[72]		\(\checkmark\)	19					\(\checkmark\)	9			\(\checkmark\)
Peeken	Europe	[73]		\(\checkmark\)	33					\(\checkmark\)	9				\(\checkmark\)	\(\checkmark\)		\(\checkmark\)
Morin	USA	[74]	\(\checkmark\)		31					\(\checkmark\)	N	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)
Anwar	USA	[75]		\(\checkmark\)	24					\(\checkmark\)	9				\(\checkmark\)			\(\checkmark\)
Opposits	Europe	[76]		\(\checkmark\)	13	\(\checkmark\)					9			\(\checkmark\)
Laprie	Europe	[77]	\(\checkmark\)		16					\(\checkmark\)			\(\checkmark\)
		[78]		\(\checkmark\)	16					\(\checkmark\)	9		\(\checkmark\)
		[79]	\(\checkmark\)		165			\(\checkmark\)					\(\checkmark\)
		[80]		\(\checkmark\)	180			\(\checkmark\)			9		\(\checkmark\)
Lopez	India/USA	[81]		\(\checkmark\)	17					\(\checkmark\)	9					\(\checkmark\)		\(\checkmark\)
Mellon	USA	[82]	\(\checkmark\)		30	\(\checkmark\)							\(\checkmark\)
Mellon	USA	[83]	\(\checkmark\)		30	\(\checkmark\)					N		\(\checkmark\)
Gurbani	USA	[84]		\(\checkmark\)	1				\(\checkmark\)		9					\(\checkmark\)

Study name	Intervention
Study name	F18-FET PET	C11-MET PET	C11-AMT PET	F18-FDOPA PET	F18-FDG PET	Ga68-FAP PET	DCE-MRI	DTI-MRI	DW-MRI	PWI-MRI	BOLD-MRI	MRSI	Boost
Niyazi	\(\checkmark\)
Niyazi	\(\checkmark\)
Piroth	\(\checkmark\)												\(\checkmark\)
	\(\checkmark\)												\(\checkmark\)
	\(\checkmark\)												\(\checkmark\)
	\(\checkmark\)												\(\checkmark\)
Laouiti	\(\checkmark\)												\(\checkmark\)
Miwa	\(\checkmark\)												\(\checkmark\)
Munck Af	\(\checkmark\)
Rosenschold	\(\checkmark\)
Lundemann	\(\checkmark\)
	\(\checkmark\)
	\(\checkmark\)				\(\checkmark\)		\(\checkmark\)		\(\checkmark\)
Poulsen	\(\checkmark\)
Poulsen	\(\checkmark\)
Harat	\(\checkmark\)
Hayes	\(\checkmark\)
Fleischmann	\(\checkmark\)
Matsuo		\(\checkmark\)
Matsuo		\(\checkmark\)
Vigil		\(\checkmark\)											\(\checkmark\)
Vigil		\(\checkmark\)											\(\checkmark\)
Hirata		\(\checkmark\)			\(\checkmark\)
Hirata		\(\checkmark\)			\(\checkmark\)
Christensen			\(\checkmark\)
Christensen			\(\checkmark\)
Kosztyla				\(\checkmark\)
Brinkmann				\(\checkmark\)									\(\checkmark\)
				\(\checkmark\)									\(\checkmark\)
				\(\checkmark\)									\(\checkmark\)
Windisch						\(\checkmark\)
Windisch						\(\checkmark\)
Munshi							\(\checkmark\)
Wahl							\(\checkmark\)		\(\checkmark\)
Kim							\(\checkmark\)		\(\checkmark\)				\(\checkmark\)
							\(\checkmark\)		\(\checkmark\)				\(\checkmark\)
							\(\checkmark\)		\(\checkmark\)				\(\checkmark\)
Berberat								\(\checkmark\)
Wang								\(\checkmark\)			\(\checkmark\)
Zhang								\(\checkmark\)
Altabella								\(\checkmark\)
Peeken								\(\checkmark\)
Morin									\(\checkmark\)
Anwar									\(\checkmark\)	\(\checkmark\)		\(\checkmark\)
Opposits											\(\checkmark\)
Laprie												\(\checkmark\)	\(\checkmark\)
												\(\checkmark\)	\(\checkmark\)
												\(\checkmark\)
												\(\checkmark\)	\(\checkmark\)
Lopez												\(\checkmark\)
Mellon												\(\checkmark\)	\(\checkmark\)
Mellon												\(\checkmark\)	\(\checkmark\)
Gurbani												\(\checkmark\)	\(\checkmark\)

RCT Randomised controlled trial, Par Participants, Q Quality (Score 1–9 or N = Non applicable, A low score is indicative of some issue with the study quality), \(\checkmark\) = Present in citation

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com

Radiation Oncology

Contact us